Apogee Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Thomas Henderson
- Full Time Employees
- 196
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 221 Crescent Street Waltham MA United States of America 02453
- IPO Date
- Jul 14, 2023
- CIK
- 0001974640
- Website
- apogeetherapeutics.com
- Similar Companies
- Business
- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company founded in 2022 and headquartered in Waltham, Massachusetts, develops novel biologics targeting inflammatory and immunological diseases, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other immune-mediated conditions; its lead product candidate, APG777, comprises a subcutaneous extended half-life monoclonal antibody (mAb) against IL-13 in Phase 2 trials for AD and Phase 1 trials for asthma and EoE; APG279 targets OX40L in preclinical development for AD; APG990 offers an SQ extended half-life mAb for AD; APG333 constitutes a human mAb against thymic stromal lymphopoietin for asthma and COPD; APG808 provides an SQ extended half-life mAb targeting IL-4Rα for Type 2 allergic diseases. The company operates primarily in the United States with a workforce of approximately 196 employees focused on advancing monotherapies and combinations to achieve best-in-class efficacy and dosing convenience for patients underserved by current standards of care in dermatology, respiratory, and gastroenterological segments. In recent developments, Apogee Therapeutics closes a $345 million follow-on equity financing in October 2025 to support clinical pipeline advancement into 2028; it progresses the Phase 2 APEX trial of APG777 in AD with Part A fully enrolled and interim 16-week data expected mid-2025 alongside Part B enrollment; the company doses the first patient in a Phase 1b asthma trial for APG777, reports positive interim APG808 results showing 53% FeNO reduction in asthma, and plans a head-to-head Phase 1b trial of APG279 versus Dupixent in AD later in 2025.
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic Dermatitis Transcript
Apogee Therapeutics to Participate in Upcoming June Conferences
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing
Apogee Therapeutics lines up $1.3B strategic financing for zumilokibart program
Blackstone Backs Apogee With Up To $1.3 Billion
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
Apogee Therapeutics: Targeting Atopic Dermatitis
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year High – Still a Buy?
Apogee Therapeutics (NASDAQ:APGE) CEO Sells $1,651,600.00 in Stock
Aberdeen Group plc Lowers Stake in Apogee Therapeutics Inc. $APGE
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors
Apogee Therapeutics (NASDAQ:APGE) Reaches New 52-Week High – Here’s Why
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone
Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript